Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
An announcement from QuantumPharm, Inc. ( (HK:2228) ) is now available.
XtalPi’s subsidiary, Ailux, has announced a strategic collaboration with Eli Lilly to enhance the development of bispecific antibodies using AI-driven technology. This partnership allows Lilly to access Ailux’s advanced antibody engineering platform, potentially leading to significant milestone payments and a total collaboration value of up to $345 million, marking a substantial impact on XtalPi’s industry positioning and stakeholder interests.
The most recent analyst rating on (HK:2228) stock is a Hold with a HK$12.00 price target. To see the full list of analyst forecasts on QuantumPharm, Inc. stock, see the HK:2228 Stock Forecast page.
More about QuantumPharm, Inc.
XtalPi Holdings Limited, founded by MIT physicists in 2015, is an innovative R&D platform utilizing quantum physics, artificial intelligence, and robotics. It offers digital and intelligent R&D solutions across various industries, including pharmaceuticals, materials science, and cosmetics. Ailux, a wholly-owned subsidiary of XtalPi, focuses on AI-powered biologics to develop advanced biotherapeutics.
Average Trading Volume: 192,771,285
Technical Sentiment Signal: Strong Buy
Current Market Cap: HK$47.27B
For an in-depth examination of 2228 stock, go to TipRanks’ Overview page.